Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Coding Corner Answer: September

Staff  |  Issue: September 2014  |  September 1, 2014

Answer

CPT: 96413, 96415 x1, J1745 x 19 J1745-JW* x 1

Diagnosis: ICD-9 714.0 and ICD-10 M05.09

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Rationale: The 2014 AMA Current Procedural Terminology manual states, “Chemotherapy administration codes 96401-96549 apply to parenteral administration of non-radionuclide anti-neoplastic drugs; and also to anti-neoplastic agents provided for treatment of non-cancer diagnoses (e.g., cyclophosphamide for auto-immune conditions) or to substances such as certain monoclonal antibody agents.”

The infliximab infusion is a highly complex biologic code, which should be coded to CPT 96413 for the first hour of infusion, and CPT 96415 is used to code each additional hour of the infusion up to eight hours. Because the patient’s infliximab was infused over two hours and 10 minutes, it is coded with both 96413 and 96415×1. Note that in order for an additional hour to be billed, the infusion would have to be at least 31 minutes into the next hour. The time does not start for the infusion until the actual medication is started, not when the IV port is inserted.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

J1745 is the drug HCPCS code for infliximab 10 mg, of which the patient received 200 mg. The correct way to code for the drug is J1745 x 20 (20 x 10 = 200 mg). According to the CMS infliximab medical policy for the diagnosis of RA, the dosage allowed is 3 mg/kg IV. If the patient currently weighs 135 lbs., that means she would be allowed 61.24 kg x 3, which equals 183.72 mg of infliximab that should be used. Because infliximab comes in 10 mg vials, the dosage would be rounded up to 19 vials. The other 10 mg would have to be documented as drug wastage and coded with a modifier JW to indicate drug wastage.

*Currently, Medicare does not require the use of the JW modifier, but still requires documentation in the medical record of any drug wastage. Many private carriers do require the use of the JW modifier with the wasted drug listed on a separate line, and the medical record must clearly document why and how much drug was wasted.

Share: 

Filed under:Billing/CodingBiologics/DMARDsDrug UpdatesFrom the CollegePractice Support Tagged with:AC&RAmerican College of Rheumatology (ACR)BillingBiologicsCodingdrugICD-10infliximabPractice Managementrheumatology

Related Articles
    Prepare NOW for ICD-10 Medical Coding Transition

    Prepare NOW for ICD-10 Medical Coding Transition

    July 14, 2015

    The ICD-10 page on the Centers for Medicare & Medicaid Services (CMS) website features a countdown clock that shows the time left until Oct. 1, 2015, the date on which compliance with the new code set becomes mandatory. By the time this issue goes to press, the clock will read 90 or fewer days. Time…

    Key Facts on Billing Drug Wastage

    January 24, 2023

    The ACR has compiled guidelines and tips on how to use the JW modifier and correctly bill Medicare for discarded drugs and biologicals. This modifier can be applied only to unused amounts from a single-dose vial or package.

    Coding Corner Answer: March

    March 1, 2015

    Coding for chemotherapy infusion with a drug reaction

    Rheumatology Coding Corner Answer: Billing Infusion Procedure with JW Modifier

    April 20, 2017

    Take the challenge. CPT: 99214-25, 96413, 96375, 96361-59, J1745 x 4 J1745 JW* x 36, J1200 x1 ad goes here:advert-1ADVERTISEMENTSCROLL TO CONTINUEICD-10: M45.09, T50.995A, R06.02, E66.3, Z68.2 Rationale Modifier 25 is appropriate to use because it indicates the patient received a significant, separately identifiable E/M service on the same day as the infliximab infusion. This…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences